awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35911679-C09C5EE2-A319-43E2-967A-25097AC67816
Q35911679-C09C5EE2-A319-43E2-967A-25097AC67816
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35911679-C09C5EE2-A319-43E2-967A-25097AC67816
Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
P2860
Q35911679-C09C5EE2-A319-43E2-967A-25097AC67816
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35911679-C09C5EE2-A319-43E2-967A-25097AC67816
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
09176141798cfd37756e723e48b433154d98f76e
P2860
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.